Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el miércoles 18/06/2025 al final de la jornada laboral. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
104
resultados
Última actualización
21/06/2025 [08:47:00]
Resultados 25 a 50 de 104
Resumen de: WO2025119153A1
Provided is a composition which can be a lyophilized preparation solution or a lyophilized powder preparation. The composition comprises a multispecific antibody, a surfactant, a buffer system, and a stabilizer/osmotic pressure regulator. Further provided are a preparation method for the composition and use of the composition, for example, use in treating tumors, especially multiple myeloma.
Resumen de: WO2025122939A1
There are provided methods for detecting and classifying a B-cell malignancy selected from the group consisting of a B-cell lymphoma, a B-cell leukemia, and a plasma cell dyscrasia in a subject. The methods employ a tumor cell profiling algorithm to analyze single-cell RNA sequencing data obtained from a sample of, e.g., the subject's blood or bone marrow, enriched for a cell type comprising tumoral cells using a cell surface marker. This algorithm identifies one or more one or more expanded clonal cell populations and categorizes each of the one or more expanded clonal cell populations as malignant or pre-malignant tumor cell population if expression of one or more malignancy markers is detected. The one or more malignant or pre-malignant tumor cell population(s) can be analyzed using a statistical model or machine learning algorithm to classify the B-cell malignancy.
Resumen de: WO2025122697A1
Various embodiments of the present disclosure provide determining a clinical diagnosis prediction and/or prognosis prediction with respect to acute myeloid leukemia (AML). A prediction model operating on a computing entity obtains subject data comprising DNA methylation data corresponding to a subject. The prediction model provides the subject data to an input layer of a machine learning-trained model configured to generate a clinical diagnosis prediction and/or a prognosis prediction for the subject based on a learned transformation of the subject data. The prediction model extracts at least one prediction from an output layer of the machine learning-trained model. The prediction model causes the at least one prediction to be provided for human review.
Resumen de: WO2025122569A1
Disclosed is a recombinant T cell receptor that recognizes the KMT2A: :AFF1 fusion neoantigen presented by HLA- DPAl*02 : 01 DPBl*01 : 01, polynucleotides encoding the recombinant T cell receptor, and an expression vector and recombinant host cell comprising such polynucleotides. A method of using the recombinant T cell receptor in adoptive immunotherapy for treating leukemia is also provided.
Resumen de: WO2025121806A1
The present invention relates to a pharmaceutical composition for prevention or treatment of cancer, comprising a BTK degrader and a METTL3 inhibitor, for which it has been confirmed that when a BTK degrader and a METTL3 inhibitor based on proteolysis-targeting chimera (PROTAC) technology are co-administered, a synergistic effect of exhibiting notable anticancer activity is achieved compared to when same are used alone, and thus a prevention or treatment effect on various cancers such as leukemia, lymphoma, lung cancer, pancreatic cancer, and breast cancer may be created.
Resumen de: WO2025121805A1
The present invention relates to a pharmaceutical composition for preventing or treating cancer, the composition comprising an EZH2 inhibitor and a JAK3 inhibitor. When an EZH2 inhibitor and a JAK3 inhibitor based on proteolysis-targeting chimera (PROTAC) technology are co-administered, a remarkable synergistic effect on anticancer activity is exhibited as compared to when either of the inhibitors is administered by itself. Thus, the present invention was found to be able to create a preventive or therapeutic effect on various cancers such as lymphoma, lung cancer, pancreatic cancer, breast cancer, and colorectal cancer.
Resumen de: WO2025121807A1
The present invention relates to a pharmaceutical composition for the prevention or treatment of cancer comprising an EZH2 inhibitor and a METTL3 inhibitor. When co-administered, the EZH2 inhibitor and METTL3 inhibitor based on proteolysis-targeting chimera (PROTAC) technology exhibit a synergistic anticancer effect that is significantly superior to individual treatments, demonstrating that the co-administration can bring about the effects of preventing or treating various cancers such as leukemia, lymphoma, lung cancer, pancreatic cancer, breast cancer, and colorectal cancer.
Resumen de: WO2025122271A1
Described are a method for allogeneic hematopoietic stem cell transplantation (HSCT), a method of treating leukemia, a method of preventing leukemic relapse in a patient in need thereof for at least one year after allogeneic hematopoietic stem cell transplantation comprising administration of a γδ T cell product after the allogeneic HSCT. The invention also encompasses a method of increasing in vivo persistence and expansion of allogeneic γδ T cells administered after allogeneic hematopoietic stem cell transplantation.
Resumen de: US2025188169A1
The disclosure provides method for treating clonal hematopoiesis disorders such as clonal hematopoiesis, myelodysplasia, and leukemia.
Resumen de: US2025189529A1
Provided herein are biomarkers and combinations of biomarkers for use in manufacturing panels for determining whether a patient is at risk for multiple myeloma precursor disease progression. Also provided herein are methods of treatment for subjects identified as being at risk for multiple myeloma precursor disease progression.
Resumen de: US2025186460A1
The present disclosure provides anti-CD19 antibodies and venetoclax for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or small lymphocytic lymphoma. The anti-CD19 antibodies, in particular MOR00208, and venetoclax are administered to patients suffering non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) according to a specific treatment paradigm to mitigate therapy associated tumor lysis syndrome.
Resumen de: US2025189516A1
The present invention relates to a method, in particular an in vitro method, for identifying an improved anti-senescence compound based on detecting the binding of said compound in the presence of at least one phosphory lated amino acid in the transcription activation domain (TAD) domain of mammalian protein p53. The present invention further relates to a method, in particular an in vitro method, for monitoring an anti-senescence treatment or prophylaxis in a mammalian subject in need thereof, based on detecting the amount of phosphorylation of amino acids in the TAD and/or C-terminal region of the mammalian p53 protein in a biological sample obtained from said subject and/or detecting the amount and/or co-localization with phosphorylated p53 of the promyelocytic leukemia protein (PML) bodies in a biological sample obtained from said subject. Furthermore, the present invention relates to a kit for performing the above methods as well as respective uses thereof. Finally, improved anti-senescence compounds or pharmaceutical compositions are provided.
Resumen de: WO2025121944A1
The present invention discloses antibodies specifically binding to canine CD20 and uses thereof. The antibody according to the present invention can be used for early diagnosis, disease progression monitoring, and treatment of B-cell lymphoma in dogs.
Resumen de: US2025188177A1
The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and/or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.
Resumen de: US2025186451A1
The present disclosure relates generally to use of a compound of formula (I), also named ASTX660 in combination therapies for treating cancer, in particular leukemia.
Resumen de: US2025186492A1
The present invention provides a CAR-T cell targeting B7-H3 and an application thereof in the treatment of acute myeloid leukemia (AML). Specifically, the present invention provides a CAR-T cell targeting B7-H3, which comprises an scFv which targets B7-H3, a 41BB costimulatory signaling molecule and a CD3ζ domain. The B7-H3-CAR-T cell of the present invention has significant specific killing toward B7-H3 positive AML tumor cells. The results of animal experiments show that the B7-H3-CAR-T cell can significantly inhibit the growth of AML tumor cells in mice, significantly prolong the survival period of mice, and has a significant anti-tumor effect in vivo. The B7-H3-CAR-T cell of the present invention can be used as a novel therapeutic method for the targeted treatment of AML, and has huge clinical application prospects.
Resumen de: US2025188545A1
Provided herein are methods of predicting the responsiveness of a lymphoma patient to a cancer treatment comprising clustering patients into subgroups of patients using gene expression levels. Also provided herein are methods of treating a lymphoma patient based on predicting the responsiveness of the lymphoma patient to a cancer treatment.
Resumen de: US2025186477A1
The present disclosure provides compositions (e.g., injectable compositions) comprising fludarabine (e.g., fludarabine phosphate), and methods of using same to treat cancers, such as a lymphoma, and/or to lymphodeplete a subject in need thereof, for example in association with a CAR-T therapeutic regimen.
Resumen de: WO2024030569A1
A novel human T-cell acute lymphoblastic leukemia (T-ALL) cell line called INB16 (ATCC Deposit no. PTA-125809) induces memory like function on natural killer cells upon contact therewith, which memory like natural killer cells have demonstrated ability to identify and kill cancer cells, including hematologic and solid tumor cells. Useful applications of the INB16 cell line include research, a cancer therapeutic agent comprising replication incompetent INB16 cells and/or membrane portions thereof for in vivo administration and restoring function of a patient's own NK cells, and related methods of treating cancer.
Resumen de: WO2024028433A1
Inventors have first investigated the impact of PIK3CA inhibition in NZBWF1/J mice a model of lymphoproliferative disorders. They randomly assigned 30 females aged of 24 weeks to receive either vehicle (n=15) or alpelisib (n=15) during 4 weeks. At the time of sacrifice, alpelisib treated mice demonstrated significantly reduced spleen size. Flow cytometry analysis revealed that B cells were significantly reduced in alpelisib treated mice and CD8 cells count corrected. They then decided to explore the relevance of alpelisib in MRL/MpJ-Faslpr/J mice (referred here as MRL-lpr), another mouse model of lymphoproliferative disorder. These mice with homozygous Fas mutation usually develop severe lymphadenoproliferation. At the time of sacrifice, MRL-lpr mice treated with alpelisib demonstrated a reduction on their spleen and lymph node sizes. Flow cytometry analysis showed correction of B cells, T cells and other immune cells in peripheral blood mononuclear cells (PBMC), lymph nodes and spleen. The invention relates to a method for treating lymphoproliferative disorder in a subject in need thereof comprising a step of administering the subject with a therapeutically effective amount of a PIK3CA inhibitor.
Resumen de: US2025177529A1
Patients with relapsing or refractory cancer have limited treatment options because the knowledge or presence of tumor-associated antigens is lacking. The proposed therapy mounts an antigen-independent anticancer response in a rapid, safe, and targeted manner due to its ability to stimulate innate immune cells in solid tumors, addressing a major, unmet major need in clinical oncology. A holistic system is disclosed capable of preparing and purifying cell samples for adoptive transfer into patients suffering from relapsing and refractory lymphomas and other solid cancers. An acoustofluidic device processes clinically relevant cell samples in a plug-and-play format, offering cell preparation speeds >100× faster than conventional CAR T-cell therapy.
Resumen de: US2025179132A1
The invention concerns a variant (double mutant form) of the survivin polypeptide; nucleic acid molecules encoding the survivin variant; antigen presenting cells (APCs) such as dendritic cells, or APC precursors, comprising the variant survivin polypeptide or encoding nucleic acid sequence; and methods for treating a malignancy, such as myeloma, or for inducing an immune response, utilizing a variant survivin polypeptide, nucleic acid molecule, or APC.
Resumen de: US2025179469A1
The present disclosure provides improved genome editing compositions and methods for editing a casitas B-lineage (Cbl) lymphoma proto-oncogene B (CBLB) gene. The disclosure further provides genome edited cells for the prevention, treatment, or amelioration of at least one symptom of, a cancer, an infectious disease, an autoimmune disease, an inflammatory disease, or an immunodeficiency.
Resumen de: WO2025114669A1
The present invention relates to a method for the in vitro or ex vivo diagnosis of the survival outcomes of a patient suffering from acute myeloid leukemia (AML), comprising a step of detecting the expression of at least newly identified AML biomarker genes.
Nº publicación: WO2025114919A1 05/06/2025
Solicitante:
SANOFI [FR]
SANOFI
Resumen de: WO2025114919A1
The present disclosure relates to methods for treating or preventing a leukemia or a myelodysplastic syndrome in a subject in need thereof, said method comprising administering to the subject an effective amount of a combination comprising: (i) a binding protein comprising a first antigen binding domain (ABD) with binding specificity to CD123 and a second (ABD) with binding specificity to NKp46; and one or both of: (ii) a BCL-2 inhibitor, and (iii) a DNA hypomethylating agent.
BOPI
Sede Electrónica
